Stock search

Ticker or company name

Compare stocks

Market: US

  • MRNAModerna
  • REGNRegeneron Pharmaceuticals
  • VRTXVertex Pharmaceuticals

Add stock

Ticker or company

Summary

MRNA
Moderna
$215,27Down −3,63%
Year: Up +795%
22/100Ratio would not consider buying
Open stock page
REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100Ratio would watch
Open stock page
VRTX
Vertex Pharmaceuticals
$537,79Down −0,15%
Year: Up +24%
72/100Best scoreRatio would consider buying
Open stock page

Verdict

VRTX has the best score (72). REGN grows revenue the fastest. REGN is the cheapest by forward P/E. REGN has the lowest debt load. VRTX has the highest net margin. MRNA has 7 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckMRNA2 ✓ 0 — 7 ✕REGN5 ✓ 2 — 2 ✕VRTX5 ✓ 3 — 1 ✕
P/E vs its history—20,533,7
P/E vs industry—20,533,7
Forward P/En/a—13,827,2
Revenue growth, YoY+13,1%+18,6%+10,5%
EPS growth, YoY—+8,3%+9,3%
Net margin−110,5%28,5%30,7%
Net debt / EBITDA—−1,4−0,6
Free cash flow−$1,97 bn$3,83 bn$3,20 bn
Share count over a year+10,3%−1,5%−0,9%
Cash runway0,8 yrsn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterMRNATTMREGNTTMVRTXTTMIndustry medianTTM
P/E TTM ↓n/aBest: 20,5Worst: 33,742,1
Forward P/E ↓n/aBest: 13,8Worst: 27,218,7
PEG ↓n/aBest: 1,2Worst: 3,04,1
P/S TTM ↓Worst: 35,8Best: 5,810,36,6
EV/EBITDA ↓Worst: 105,9Best: 18,229,628,2
P/FCF ↓Worst: 101,4Best: 27,241,926,0

Price, %

  • MRNAn/a
  • REGNn/a
  • VRTXn/a

Returns

Best WorstNo mark — in between

PeriodMRNAREGNVRTX
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

MRNAREGNVRTX
Share of “buy”Worst: 32%72%Best: 82%
Beat the forecastBest: 4 of 4Best: 4 of 4Worst: 1 of 4
Average “surprise”Best: +43,7%+16,8%Worst: −1,5%
Insiders over 12 monthssales $78,9 msales $57,9 msales $129 m

Details are on each stock page.